Sec. Viral Immunology
Corrigendum: Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients
- 1The Wistar Institute, Philadelphia, PA, United States
- 2The Burnet Institute, Melbourne, VIC, Australia
- 3Department of Infectious Diseases, Monash University, Melbourne, VIC, Australia
- 4Rush Center for Integrated Microbiome and Chronobiology Research, Rush University, Chicago, IL, United States
- 5Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States
By Giron LB, Dweep H, Yin X, Wang H, Damra M, Goldman AR, Gorman N, Palmer CS, Tang H-Y, Shaikh MW, Forsyth CB, Balk RA, Zilberstein NF, Liu Q, Kossenkov A, Keshavarzian A, Landay A and Abdel-Mohsen M (2021). Front. Immunol. 12:686240. doi: 10.3389/fimmu.2021.686240
In the original article, there was a typo in Figure 1E, Supplementary Figure 3, and Supplementary Table 10 as published. The unit of the β-glucan should have been (pg/ml) instead of (ng/ml). The corrected Figure 1, Supplementary Figure 3, and Supplementary Table 10 appear below.
Figure 1 Severe COVID-19 is associated with an increase in markers of tight junction permeability and microbial translocation. (A) An overview of the main cohort study design; moderate and severe patients were hospitalized; severe indicates patients in the intensive care unit. (B) Levels of plasma zonulin, are higher during moderate and severe COVID-19 compared to mild COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. False discovery rate (FDR) was calculated using the Benjamini-Hochberg method. Symbols in black indicate deceased. (C) Zonulin levels are higher in hospitalized COVID patients (n=40) who eventually died from COVID-19 (n=8) compared to survivors (n=32). Nominal P-value was calculated using the Mann–Whitney U test. (D–G) Levels of LBP (D), β-Glucan (E), sCD14 (F), and MPO (G), are higher during severe COVID-19 compared to mild COVID-19 or controls. Kruskal–Wallis test was used for statistical analysis. FDR was calculated using Benjamini-Hochberg method. Black dots indicate deceased.
The authors apologize for this error and state that this does not change any of the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.779064/full#supplementary-material
Keywords: SARS-CoV-2, COVID-19, microbial translocation, inflammation, zonulin, metabolomics, glycomics, lipidomics
Citation: Giron LB, Dweep H, Yin X, Wang H, Damra M, Goldman AR, Gorman N, Palmer CS, Tang H-Y, Shaikh MW, Forsyth CB, Balk RA, Zilberstein NF, Liu Q, Kossenkov A, Keshavarzian A, Landay A and Abdel-Mohsen M (2021) Corrigendum: Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. Front. Immunol. 12:779064. doi: 10.3389/fimmu.2021.779064
Received: 17 September 2021; Accepted: 21 September 2021;
Published: 04 October 2021.
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2021 Giron, Dweep, Yin, Wang, Damra, Goldman, Gorman, Palmer, Tang, Shaikh, Forsyth, Balk, Zilberstein, Liu, Kossenkov, Keshavarzian, Landay and Abdel-Mohsen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohamed Abdel-Mohsen, firstname.lastname@example.org